Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

1. Maertens,J.A.
2. Thompson,G.R.
3. Spec,A.
4. Donovan,F.M.
5. Hammond,S.P.
6. Bruns,A.H.W.
7. Rahav,G.
8. Shoham,S.
9. Johnson,R.
10. Rijnders,B.
11. Schaenman,J.
12. Hoenigl,M.
13. Morrissey,C.O.
14. Mehta,S.R.
15. Heath,C.H.
16. Koehler,P.
17. Paterson,D.L.
18. Slavin,M.A.
19. Fortún,J.
20. Nguyen,M.H.
21. Patterson,T.F.
22. Uspenskaya,O.
23. Van de Veerdonk,F.L.
24. Verweij,P.E.
25. Aoun,M.
26. Georgala,A.
27. Alexander,B.D.
28. Chayakulkeeree,M.
29. Mehra,V.
30. Miceli,M.H.
31. Sikka,M.K.
32. Solé,A.
33. Walsh,T.J.
34. Aguado,J.M.
35. Holland,S.M.
36. Moussa,M.
37. Rautemaa-Richardson,R.
38. Bazaz,R.
39. Schwartz,S.
40. Walsh,S.R.
41. Plate,M.
42. Yehudai-Ofir,D.
43. Brüggemann,R.J.
44. Cornely,O.A.
45. Ostrosky-Zeichner,L.
46. Vazquez,J.A.
47. White,P.L.
48. Cornelissen,K.
49. Ross,G.G.
50. Fitton,L.
51. Dane,A.
52. Zinzi,D.
53. Rex,J.H.
54. Chen,S.C.-A.
55. Show all authors +